Another gene therapy has come under scrutiny in the Netherlands for its high price. ZIN, the Dutch health technology appraisal (HTA) body, says bluebird bio should reduce the price of Zynteglo (betibeglogene autotemcel), and agree to a pay-for-performance deal.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?